John B. Buse, MD, PhD, is the Verne S. Caviness Distinguished Professor of Medicine at the University of North Carolina–Chapel Hill School of Medicine’s Division of Endocrinology and Metabolism.
John Buse, MD, PhD, breaks down the 2026 American Diabetes Association (ADA) hyperglycemia guidance update, including earlier glucagon-like peptide-1 (GLP-1) receptor agonist and sodium-glucose cotransporter 2 (SGLT-2) inhibitor use and a broader holistic care framework.
John Buse, MD, PhD discusses the expanding role of GLP-1 receptor agonists in treatment of cardiovascular conditions.
